Thrombin activatable fibrinolysis inhibitor (TAFI) in cord blood

Folia Histochemica et Cytobiologica

Volumn 45, Issue 1, 2007, Pages 33-36

  Uszyński, Waldemar ^a   Uszyński, Mieczysław ^b   Zekanowska, Ewa ^b   Góralczyk, Krzysztof ^b  

^a Obstetric Gynecological Ward of the Regional Hospital in W oc awek   (Poland)

^b NICOLAUS COPERNICUS UNIVERSITY   (Poland)

Author keywords

Cord blood; Fibrinolysis; TAFI

Indexed keywords

CITRATE SODIUM; THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR;

ADULT; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DELIVERY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FETUS BLOOD; HUMAN; MATERNAL BLOOD; MULTIPARA; PREGNANCY; PRIMIPARA; UMBILICAL CORD BLOOD;

EID: 33947248114     PISSN: 02398508     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Antović JP, Hamad RR, Antović A, Blombäck M, Bremme K. Does thrombin activatable fibrinolysis inhibitor (TAFI) contribute to impairment of fibrinolysis in patients with preeclampsia and/or intrauterine fetal growth retardation? Thromb Haemost, 2002; 88: 644-47
2. Antović JP, Antović A. Does recombinant factor VIIa, apart from overall hemostasis, regulate TAFI dependent fibrinolysis? In vitro analysis using overall hemostasis potential (OHP) assay. Thromb Haemost, 2003; 90: 620-27
3. Alacacioglu IA, Ozcan MA, Oglu AA, Polat M, Yuksel F, Demirkan F, Piskin O, Ozgenc Y., Ozsan GH, Undar B. Plasma levels of thrombin activitable fibrinolysis inhibitor in normal and preeclamptic pregnant women. Thromb Res, 2004; 114: 155-59
4. Bajzar L, Morser J, Neisheim ME. Purification and characterization of TAFI, a thrombin activatable fibrinolysis inhibitor. J Biol Chem, 1995; 270: 14477-84
5. Booth NA. TAFI meets the sticky ends. Thromb Haemost, 2001; 85: 1-2
6. Campbell W, Okada N, Okada H. Carboxypeptidase R is an inactivator of complement-derived inflammatory peptides and an inhibitor of fibrinolysis. Immunol Rev, 2001; 180: 162-67
7. Chabloz P, Reber G, Boehlen F. TAFI antigen and D-dimer levels during normal pregnancy and at delivery. Br J Haemost, 2001; 115: 150-52
8. Chetaille P, Kouassi AD, Morange PE, Juhan-Vague I. Plasma TAFI antigen variations in healthy subjects. Thromb Haemost, 2000; 83: 902-05
9. Lau HK, Segev A, Hegele RA, Sparkes JD, Teitel JM, Chisholm RJ, Strauss BH. Thrombin-activitable fibrinolysis inhibitor (TAFI): a novel predictor of angiographic coronary restenosis. Thromb Haemost, 2003; 90: 1187-91
10. Lisman T, Leebeek F-W, Mosnier L-O, Bouma BN, Meijers JC, Janssen HL, Nieuwenhuis HK, de Groot PG. Thrombin-actavatable fibrinolysis inhibitor deficiency in cirrhosis is not associated with increased plasma fibrinolysis. Gastroenterology, 2001; 121: 131-9
11. Lisman T, Mosnier LO, Lambert T, Mausner-Bunschoten EP, Meijers JC, Nieuwenhuis HK, de Groot PG. Inhibition of fibrinolysis by recombinant factor VIIa in plasma from patients with severe hemophilia A. Blood, 2002; 99: 175-9
12. Morange PE, Juhan-Vague I, Scarabin PY, Alessi MC, Luc G, Arveiler D, Ferrieres J, Amouyel P, Evans A, Ducimetiere P, PRIME Study group. Association between TAFI antigen and Ala I 47Thr polymorphism of the gene and the angina pectoris insidence. Thromb Haemost, 2003; 89: 554-60
13. Mousa HA, Downey C, Alfirevic Z, Toh Ch-H. Thrombin activitable fibrinolysis inhibitor and its fibrinolytic effect in normal pregnancy. Thromb Haemost, 2004; 92: 1025-31
14. Stromqvist M, Schatteman K, Leurs J, Leurs J, Verkerk R, Anderssen JO, Johansson T, Scharpe S, Hendriks D. Immunological assay for the determination of procarboxypeptidase U antigen levels in human plasma. Thromb Haemost, 2001; 35: 12-17
15. Van Thiel DH, George M, Fareed J. Low levels of thrombin activatable fibrinolysis inhibitor (TAFI) in patients with chronic liver disease. Thromb Haemost, 2001; 85: 667-70
16. Uszyński W, Zekanowska E, Szymański W, Uszyński M. Thrombin activatable fibrinolysis inhibitor (TAFI) in cord blood and blood of mother during labour (in Polish). XXIII Kongres Polskiego Towarzystwa Ginekologicznego. Ginek Pol, 2003; 74: 1329-34
17. Wang W, Boffa MB, Bajzar L, Walker JB, Nesheim ME. A study of the mechanism of fibrinolysis by activated thrombin-activitable fibrinolysis inhibitor. J Biol Chem, 1998; 273: 27176-81
18. Watanabe R, Wada H, Watanabe Y, Sakakura M, Nakasaki T, Mori Y, Nishikawa M, Gabazza EC, Nobori T, Shiku H. Activity and antigen levels of thrombin - activatable fibrinolysis inhibitor in plasma of patients with disseminated intravascular coagulation. Thromb Res, 2001; 104: 1-6
19. Watanabe T, Minakami H, Sakata Y, Matsubara S, Sato I, Suzuki M. Changes in activity of plasma thrombin activitable fibrinolysis inhibitor in pregnancy. Gynecol Obstet Invest, 2004; 58: 19-21